We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Vieni Global aim to make bus travel smart and efficient by using smart data to meet demand in real time. Vieni uses an economy sharing model to help users collectivise their demands. When they do this, they reduce costs, reduce carbon emissions and increase comfort and convenience.
days to go: Expired investment: £18,943
The Cauldron is a technology-led entertainment studio that aims to deliver immersive experiences to its guests by combining technology with food and drink. Upon entering the company's venues, guests are given a magic wand, which acts as a control device for their visit. It helps them pour pints, activate lights and locks, explore science experiments, and stir cocktails. The device is also programmed to act as an open bar tab to track user spending. The Cauldron has served 1 million potions till date and welcomed 260,000+ guests. It has also inked ticket and product selling partnerships with entities like TimeOut, Airbnb Experiences, Secret London, Virgin Experience Days, and others. The company has featured on publications like Thrillist, NBC, Forbes, and Edinburgh News. The Cauldron will use 70% of the investment to open a central-London Cauldron flagship and provide additions to Wands & Wizard Exploratorium, 20% to finish the build for three new pop-up venues to open in markets across the US and Europe, and 10% to pay staff salaries.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £304,690
Ombar is re-defining chocolate by making premium chocolate bars from unroasted raw cacao and other natural, healthy ingredients.
days to go: Expired investment: £354,000
Northern Monk is a brewery.  They started from their family home using other peoples breweries across Yorkshire and selling at farmers markets.  In 2014 they found and restored a grade 2 listed building and turned it into a brewery, tap room and arts/events space and have added a second brewery close by.  The investment will help them triple their capacity with 8 new 10,000 litre fermentation vessels and make production quicker, more efficient and reduce down time and waste with a new packaging line.
days to go: Expired investment: £1,482,740
planarTECH is an engineering company founded in 2014 as a provider of process equipment for the growth and characterisation of graphene and other emerging 2D materials. Its core product line is the planarGROW Chemical Vapor (CVD) system. The company has the ability to deliver scalable production systems that allow lower-cost production of graphene in comparison to other options currently available in the market. Moreover, from 2014 to 2019, the company’s cumulative revenues exceeded £5 million. The company's products have been installed and used by faculties and students at prestigious universities like Stanford University (USA), IIT- Bombay (India), Deakin University (Australia), and many others. From the investment, the company will utilise 45% as working capital, 30% in Capital Expenditures (CAPEX), 15% in R&D and 10% in hiring additional staff.

Pitch Rated

47%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £425,061
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph